Akeso and Summit Therapeutics (SMMT) have reported a significant breakthrough in the treatment of non-small cell lung cancer with their jointly developed drug ivonescimab.
The bispecific antibody reduced the risk of death by 27% compared with Keytruda in the phase 3 Harmoni-2 trial, marking a notable clinical milestone.
The trial focused on first-line treatment in patients with PD-L1-positive non-small cell lung cancer, one of the most common and difficult-to-treat cancer types globally.
Keytruda, developed by Merck (MRK), has long been considered the gold standard in first-line treatment for this patient population, making the results particularly striking.
The Harmoni-2 data adds to growing evidence that ivonescimab may represent a genuine step forward in outcomes for lung cancer patients.
Results were especially strong among patients in the PD-L1-high subgroup, suggesting the drug may deliver its greatest benefit to those with the highest expression of the biomarker.
PD-L1-high patients are typically considered strong candidates for immunotherapy, and the data indicates ivonescimab could outperform existing standard-of-care options in this group.
Ivonescimab is a bispecific antibody that targets both PD-1 and VEGF pathways simultaneously, a dual mechanism of action that distinguishes it from single-pathway checkpoint inhibitors like Keytruda.
This combined approach is designed to deliver both immune activation and anti-angiogenic effects, potentially producing a more comprehensive anti-tumour response than existing therapies.
Akeso, the Chinese biotechnology company that developed the molecule, partnered with Summit Therapeutics to advance the drug through global clinical trials and commercialisation.
The Harmoni-2 trial results position ivonescimab as a serious contender in the competitive non-small cell lung cancer treatment landscape, where new options are urgently needed.
Non-small cell lung cancer accounts for the vast majority of all lung cancer diagnoses, and first-line treatment decisions carry significant implications for patient survival and quality of life.
The strength of the overall survival data against an established and widely approved therapy is expected to attract considerable attention from oncologists and regulators alike.
Summit Therapeutics holds the rights to develop and commercialise ivonescimab outside of Greater China, giving the company a substantial commercial opportunity if regulatory approvals follow.
The Harmoni-2 findings are likely to support future regulatory submissions, with analysts watching closely for the next steps from both Akeso and Summit.